Sort by
Refine Your Search
-
Listed
-
Employer
- University of British Columbia
- University of Waterloo
- Dalhousie University
- Ryerson University
- Nature Careers
- McGill University
- University of Saskatchewan
- Fields Institute
- Institut national de la recherche scientifique (INRS)
- Northern Alberta Institute of Technology
- Queen's University
- The University of British Columbia (UBC)
- University of Alberta
- 3 more »
- « less
-
Field
-
clinically-approved drugs for indications related to wound healing. The Granville research program spans basic molecular biology and biochemistry through to target validation, proof-of-concept in animal and
-
bioinformatics team of the BC Cancer’s Department of Molecular Oncology (http://molonc.bccrc.ca). The UBC Department of Obstetrics & Gynaecology has training programs at the undergraduate, graduate and
-
benefits plan, including extended health and dental coverage Applications will be reviewed on a rolling basis until the position is filled. Please send application materials to travis.dewolfe@bccsu.ubc.ca
-
-year, with the potential to extend) Compensation: $60,000 per year Desired Start Date: April 1, 2025 Benefits: UBC offers a comprehensive benefits plan, including extended health and dental coverage
-
More Topics #jobs The Transformative Quantum Technologies (TQT) program at the University of Waterloo has several openings for Postdoctoral Fellowships (PDFs). These prestigious positions
-
, or forest management. Project Overview The postdoc will contribute to the Silva21 research program, which aims to develop innovative strategies to enhance the resilience of Canadian forests in the face of
-
to be considered for this opportunity. About NAIT We are proud to have been named one of Alberta’s Top Employers for 14 consecutive years. Being part of a community that makes a difference in the lives
-
academic disciplines are encouraged to apply, including—but not limited to—philosophy, theology, psychology, sociology, political science, law, literature, and the arts. The program is open to U.S. and
-
. Potential projects focus on severe ADRs to a range of different medications. Current priority ADRs include cisplatin-induced ototoxicity, anthracycline-induced cardiotoxicity, COVID-19 vaccine-induced
-
on the genetic determinants of severe adverse drug and vaccine reactions. Potential projects focus on severe ADRs to a range of different medications. Current priority ADRs include cisplatin-induced